01:17 PM EDT, 04/28/2025 (MT Newswires) -- Chemomab Therapeutics ( CMMB ) reported positive results from a Phase 2 trial of nebokitug, a treatment for primary sclerosing cholangitis and other fibro-inflammatory diseases.

Patients treated with nebokitug exhibited significant changes in several proteins associated with fibrosis, inflammation and immune system activity with the effects increasing at higher doses, the company said Monday in a statement.

The data showed that the nebokitug treatment reduced biological processes tied to fibrosis and inflammation, the company said.

Nebokitug also lowered proteins involved in immune cell movement, inflammatory signals and collagen binding, the company said.

Shares of the company rose 1.5% in recent Monday trading.

Price: 1.33, Change: +0.02, Percent Change: +1.53